NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Mouse Mammary Tumor Models of Various Molecular Subtypes Including Basal-like and Claudin-low TNBC

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics differences as drivers of metastasis

Synergy of chemotherapy and macrophage depletion leads to T cell memory activation and durable triple negative breast cancer regression

Molecular signatures of in-situ to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study [human]

Molecular signatures of in-situ to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study [mouse]

Molecular signatures of in-situ to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study

Molecular signatures of in-situ to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study [CGH]

Integrated Metabolic Profiling and Gene Expression Analysis Reveals Therapeutic Modalities in Breast Cancer

RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

CALGB 40603: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Single Cell sequencing of tumor infiltrating immune cells upon E2 treatment

MultiK: An Automated Tool to Infer Optimal Cluster Numbers in Single-Cell RNA Sequencing Data

Characterization of transcriptional analysis of LKB1 mutant lung nodules

DIMETHYLBENZANTHRACENE (DMBA) INDUCED MAMMARY CARCINOGENESIS IN MMTV-Neu and MMTV/p53 KO FEMALE MICE AND EFFECTS OF REXINOIDS

Understanding BRCA1 function in INK4-RB deficient tumors

FGFR4 is a regulator of tumor subtype differentiation in luminal breast cancer and metastatic disease II

FGFR4 is a regulator of tumor subtype differentiation in luminal breast cancer and metastatic disease

FGFR4 is a key regulator of tumor subtype differentiation in luminal breast cancer and metastatic disease [set 1]

FGFR4 is a key regulator of tumor subtype differentiation in luminal breast cancer and metastatic disease [set 2]